An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 25, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)
Interventions
DRUG

Allogeneic NK(CCT-ANK-11)

allogeneic natural killer cells

All Listed Sponsors
lead

Beijing Kejing Biotechnology Co., Ltd.

INDUSTRY